891854-66-3

Upstream product

• 891854-14-1 3-(4-hydroxypiperidin-1-yl)benzonitrile 
• 124-63-0 methanesulfonyl chloride 
• 403-54-3 m-Fluorobenzonitrile 
• 5382-16-1 4-HYDROXYPIPERIDINE 

Downstream Products

• 334793-08-7 3-{3-[4-(pyrimidin-2-ylamino)-piperidin-1-yl]-benzoylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid tert-butyl ester 
• 334793-04-3 tert-butyl (2S)-{2-(morpholin-4-yl)acetylamino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 334793-09-8 (S)-3-{3-[4-(Pyrimidin-2-ylamino)-piperidin-1-yl]-benzoylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid 
• 334793-05-4 (2S)-{2-(morpholin-4-yl-acetyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]-propionic acid 
• 334793-12-3 tert-butyl (2S)-(4-methoxybenzenesulfonyl)amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 334792-98-2 tert-butyl (2S)-(benzyloxycarbonyl)amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 334793-17-8 (2S)-(4-hydroxybenzenesulfonyl)amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid 
• 334793-13-4 (2S)-{(4-methoxybenzenesulfonyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]-propionic acid 
• 334792-18-6 t-butyl (2S)-benzenesulfonylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]-propionate 
• 334792-19-7 (2S)-benzenesulfonylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid 
• 334793-00-9 tert-butyl (2S)-acetylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 334793-01-0 (2S)-acetamido-3-[3-{4-(pyrimidin-2-ylamino)-piperidin-1-yl}benzoylamino]propionic acid 
• 334792-99-3 tert-butyl (2S)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 334792-17-5 3-{4-(Pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 

Relevant academic research and scientific papers

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

To establish the in vivo efficacy of αvβ3/αIIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially too